Interleukin 6 blockade for hyperimmunoglobulin D and periodic fever syndrome.

Abstract

Hyperimmunoglobulin D and periodic fever syndrome (HIDS) is a rare, autoinflammatory condition caused by mutations in the mevalonate kinase gene. There is no standard treatment for HIDS, and randomized controlled trials are lacking. Corticosteroids, colchicine, nonsteroidal anti-inflammatory drugs, statins, and cyclosporine are of limited efficacy in controlling this condition. Recent case reports suggest that most patients respond to etanercept or anakinra. Interleukin 6 blockade in HIDS has not been described. We report the case of a 13-year-old girl with HIDS, who failed to respond to colchicine, corticosteroids, etanercept, and anakinra but was successfully treated with the anti-IL-6 monoclonal antibody, tocilizumab.

• Authors: Hiba M Shendi, Lisa A Devlin, John David Edgar
• Journal: Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases (J Clin Rheumatol) Vol. 20 Issue 2 Pg. 103-5 (Mar 2014) ISSN: 1536-7355 [Electronic] United States
• PMID: 24561416 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal, Humanized
• Immunoglobulin G
• Interleukin 1 Receptor Antagonist Protein
• Interleukin-6
• Receptors, Tumor Necrosis Factor
• tocilizumab
• Etanercept
• Colchicine

Topics

• Adolescent
• Antibodies, Monoclonal, Humanized (immunology, therapeutic use)
• Colchicine (therapeutic use)
• Etanercept
• Female
• Humans
• Immunoglobulin G (therapeutic use)
• Interleukin 1 Receptor Antagonist Protein (therapeutic use)
• Interleukin-6 (antagonists & inhibitors, immunology)
• Mevalonate Kinase Deficiency (drug therapy)
• Receptors, Tumor Necrosis Factor (therapeutic use)
• Treatment Failure
• Treatment Outcome